A compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof: wherein is selected from R 1 is selected from hydrogen, a 5- to 6- membered heteroaryl, C 1-6 alkyl, and C 1-6 haloalkyl, wherein said heteroaryl and alkyl is substituted with 0, 1, 2, or 3 moieties each independently selected from C 1-6 alkyl, halogen, and OH. R 2 is hydrogen or C 1-6 alkyl; R 3 is selected from hydrogen, C 1-6 alkyl, and cyano; R 4 is selected from hydrogen, cyano, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-12 heterocycloalkylC 0-6 alkyl, C 3-12 cycloalkylC 0-6 alkyl, arylC 0-6 alkyl, heteroarylC 0-6 alkyl, spirocyclylC 0-6 alkyl, C 3-12 cycloalkylC 0-10 alkyloxy, amino, -amino(C 1-10 alkyl) 1-2, C 3-12 cycloalkylC 0-10 alkylamino, heteroarylC 0-10 alkylamino, C 3-12 heterocycloalkylC 0-10 alkylamino, arylC 0-10 alkylamino, hydroxy, -(C 1-10 alkyl)OH, and C 1-10 alkoxy; wherein R 4 is substituted with 0, 1, 2, or 3 groups selected from C 1-6 alkyl, cyano, halogen, hydroxy, -O-C 1-6 alkyl, and -(C 1-10 alkyl)OH; further wherein, optionally, R 3 and R 4 along with the carbon to which they are attached may join together to form a 4 to 6 membered saturated ring system substituted with 0, 1, or 2 moieties selected from C 1-6 alkyl, halogen, hydroxy, -O-C 1-6 alkyl, -(C 1-10 alkyl)OH,-SO 2 C 1-6 alkyl, -SO 2 CF 3, -SO 2 CF 2 H, and C 3-12 cycloalkylC 0-10 alkylcarbonyl; R 5 is selected from hydrogen, C 1-6 alkyl, C 1-10 alkylcarbonyl, C 3-12 cycloalkylC 0-10 alkyl, C 3-12 heterocycloalkylC 0-10 alkyl, arylC 0-10 alkyl, and -(C 1-10 alkyl)OH; and R 6 is hydrogen, oxo (=O), or C 1-3 alkyl. is selected from R 1 is selected from hydrogen, a 5- to 6- membered heteroaryl, C 1-6 alkyl, and C 1-6 haloalkyl, wherein said heteroaryl and alkyl is substituted with 0, 1, 2, or 3 moieties each independently selected from C 1-6 alkyl, halogen, and OH. R 2 is hydrogen or C 1-6 alkyl; R 3 is selected from hydrogen, C 1-6 alkyl, and cyano; R 4 is selected from hydrogen, cyano, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-12 heterocycloalkylC 0-6 alkyl, C 3-12 cycloalkylC 0-6 alkyl, arylC 0-6 alkyl, heteroarylC 0-6 alkyl, spirocyclylC 0-6 alkyl, C 3-12 cycloalkylC 0-10 alkyloxy, amino, -amino(C 1-10 alkyl) 1-2, C 3-12 cycloalkylC 0-10 alkylamino, heteroarylC 0-10 alkylamino, C 3-12 heterocycloalkylC 0-10 alkylamino, arylC 0-10 alkylamino, hydroxy, -(C 1-10 alkyl)OH, and C 1-10 alkoxy; hydrogen, cyano, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-12 heterocycloalkylC 0-6 alkyl, C 3-12 cycloalkylC 0-6 alkyl, arylC 0-6 alkyl, heteroarylC 0-6 alkyl, spirocyclylC 0-6 alkyl, C 3-12 cycloalkylC 0-10 alkyloxy, amino, -amino(C 1-10 alkyl) 1-2, C 3-12 cycloalkylC 0-10 alkylamino, heteroarylC 0-10 alkylamino, C 3-12 heterocycloalkylC 0-10 alkylamino, arylC 0-10 alkylamino, hydroxy, -(C 1-10 alkyl)OH, and C 1-10 alkoxy; wherein R 4 is substituted with 0, 1, 2, or 3 groups selected from C 1-6 alkyl, cyano, halogen, hydroxy, -O-C 1-6 alkyl, and -(C 1-10 alkyl)OH; further wherein, optionally, R 3 and R 4 along with the carbon to which they are attached may join together to form a 4 to 6 membered saturated ring system substituted with 0, 1, or 2 moieties selected from C 1-6 alkyl, halogen, hydroxy, -O-C 1-6 alkyl, -(C 1-10 alkyl)OH,-SO 2 C 1-6 alkyl, -SO 2 CF 3, -SO 2 CF 2 H, and C 3-12 cycloalkylC 0-10 alkylcarbonyl; R 5 is selected from hydrogen, C 1-6 alkyl, C 1-10 alkylcarbonyl, C 3-12 cycloalkylC 0-10 alkyl, C 3-12 heterocycloalkylC 0-10 alkyl, arylC 0-10 alkyl, and -(C 1-10 alkyl)OH; and hydrogen, C 1-6 alkyl, C 1-10 alkylcarbonyl, C 3-12 cycloalkylC 0-10 alkyl, C 3-12 heterocycloalkylC 0-10 alkyl, arylC 0-10 alkyl, and -(C 1-10 alkyl)OH; and R 6 is hydrogen, oxo (=O), or C 1-3 alkyl.